Besamusca F W, Bastiaensen L A
Doc Ophthalmol. 1986 Dec 30;64(1):87-95. doi: 10.1007/BF00166689.
The case reports presented so far, concerning a possible causative relationship between the ophthalmological use of chloramphenicol (O-CAP) and blood dyscrasias, are few in number, not always fully documented and therefore not always convincing. The overall use of this drug in a restricted area in the Netherlands was assessed. On a yearly basis 1:29 people used O-CAP. In a four-year period in the same area, 12 patients with aplastic anemia and 190 patients with other cytopenic dyscrasias were found. After exclusion of all cases with other possible causes of the dyscrasia, e.g. cancer and related therapy, other drugs than O-CAP and infectious diseases, 59 cases remained in which a definite cause could not be established. We traced back the use of O-CAP in the relevant period. No dyscrasias were found that unequivocally were caused by O-CAP. The rate of O-CAP use in the dyscrasia-group was approximately equal to that in the population as a whole. Hence we concluded that it is highly improbable that O-CAP played a part in the etiology of blood dyscrasias in the region. Statistical evaluation of material derived from a much larger region may, however, lead to a more differentiated conclusion.
迄今为止所呈现的病例报告，涉及氯霉素眼科用药（O-CAP）与血液系统疾病之间可能的因果关系，数量较少，且并非总是有充分记录，因此并不总是令人信服。对荷兰某一特定地区该药物的总体使用情况进行了评估。每年有1/29的人使用O-CAP。在同一地区的四年时间里，发现了12例再生障碍性贫血患者和190例其他血细胞减少性血液系统疾病患者。在排除了所有由其他可能导致血液系统疾病的原因，如癌症及相关治疗、除O-CAP之外的其他药物以及传染病之后，仍有59例病例无法确定明确病因。我们追溯了相关时期内O-CAP的使用情况。未发现明确由O-CAP导致的血液系统疾病。血液系统疾病组中O-CAP的使用率与总体人群大致相当。因此我们得出结论，在该地区，O-CAP极不可能在血液系统疾病的病因中起作用。然而，对来自更大区域的资料进行统计学评估可能会得出更具区分性的结论。
